1. Efficacy and safety of OBI‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. (27th January 2015) Authors: Kruse‐Jarres, R.; St‐Louis, J.; Greist, A.; Shapiro, A.; Smith, H.; Chowdary, P.; Drebes, A.; Gomperts, E.; Bourgeois, C.; Mo, M.; Novack, A.; Farin, H.; Ewenstein, B. Journal: Haemophilia Issue: Volume 21:Number 2(2015:Mar.) Page Start: 162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of OBI‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. (27th January 2015) Authors: Kruse‐Jarres, R.; St‐Louis, J.; Greist, A.; Shapiro, A.; Smith, H.; Chowdary, P.; Drebes, A.; Gomperts, E.; Bourgeois, C.; Mo, M.; Novack, A.; Farin, H.; Ewenstein, B. Journal: Haemophilia Issue: Volume 21:Number 2(2015:Mar.) Page Start: 162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis. Issue 5 (22nd June 2017) Authors: Kenet, G.; Oladapo, A.; Epstein, J.D.; Thompson, C.; Novack, A.; Nugent, D. J. Journal: Haemophilia Issue: Volume 23:Issue 5(2017) Page Start: e394 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗